Results 31 to 40 of about 38,009 (171)

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

The role of harms and burdens in clinical practice guidelines: Lessons learned from the American Psychological Association's guideline development

Clinical Psychology: Science and Practice, EarlyView., 2020
Abstract Growing evidence supports the efficacy of various psychosocial interventions yet provides very little information about the potential harms and burdens of treatment. Lacking such information makes it difficult to make truly informed decisions about treatment options.
Raquel W. Halfond, Caroline Vaile Wright, Lynn F. Bufka   +2 more
wiley   +1 more source

Testing of analgesic effect of fluoxetine

Biomolecules & Biomedicine, 2004
Fluoxetine is used in treatment of depression caused by a variety of different factors and from year to year new indications are being added, especially in conditions followed with strong bouts of pain.
Amra Begović, İrfan Zulić, Fahir Becić   +2 more
doaj   +1 more source

Differential Rearing Alters Forced Swim Test Behavior, Fluoxetine Efficacy, and Post-Test Weight Gain in Male Rats. [PDF]

PLoS ONE, 2015
Environmental factors play a key role in the etiology of depression. The rodent forced swim test (FST) is commonly used as a preclinical model of depression, with increases in escape-directed behavior reflecting antidepressant effects, and increases in ...
David L Arndt, Christy J Peterson, Mary E Cain   +2 more
doaj   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Fluoxetine brakes the menstrual cycle: Uncovering the unexpected effect

Industrial Psychiatry Journal
Fluoxetine is one of the most commonly used antidepressants, classified under selective serotonin reuptake inhibitors (SSRIs). It is indicated for the treatment of depression, obsessive-compulsive disorder, anxiety, and eating disorders.
Barath Ramanathan, Souganya Vijayan, Perarul Sivakumar, Arun Selvaraj   +3 more
doaj   +1 more source

Corticosterone facilitates fluoxetine-induced neuronal plasticity in the hippocampus.

PLoS ONE, 2013
The hippocampal dentate gyrus has been implicated in a neuronal basis of antidepressant action. We have recently shown a distinct form of neuronal plasticity induced by the serotonergic antidepressant fluoxetine, that is, a reversal of maturation of the ...
Katsunori Kobayashi, Yumiko Ikeda, Minoru Asada, Hirofumi Inagaki, Tomoyuki Kawada, Hidenori Suzuki   +5 more
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Fluoxetine increases astrocytic glucose uptake and glycolysis in corticosterone-induced depression through restricting GR-TXNIP-GLUT1 Pathway

Frontiers in Pharmacology, 2022
Antidepressant fluoxetine can affect cerebral glucose metabolism in clinic, but the underlying molecular mechanism remains poorly understood. Here, we examined the effect of fluoxetine on brain regional glucose metabolism in a rat model of depression ...
Shu-Man Pan, Yi-Fan Zhou, Na Zuo, Rui-Qing Jiao, Ling-Dong Kong, Ling-Dong Kong, Ying Pan, Ying Pan   +7 more
doaj   +1 more source

Exploring Cerumen as an Alternative Matrix for Drug Detection and Quantification: Method Development and Application in Clinical Samples

Drug Testing and Analysis, EarlyView.
An LC–MS/MS method was developed for the detection of 33 psychoactive medications in cerumen (earwax) and applied to the samples of 60 psychiatric inpatient volunteers. The findings highlighted the utility of cerumen as an innovative biospecimen in clinical toxicological analysis.
Dimitrios Phaedon Kevrekidis, Helen G. Gika, Georgios Panagiotoglou, Eleni Parlapani, Pavlos Pavlidis, Nikolaos Raikos   +5 more
wiley   +1 more source